Statin use is associated with the reduction in hepatocellular carcinoma recurrence after liver surgery.
Carcinoma, Hepatocellular
/ drug therapy
Disease-Free Survival
Hepatectomy
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ therapeutic use
Liver Neoplasms
/ drug therapy
Neoplasm Recurrence, Local
/ prevention & control
Odds Ratio
Postoperative Period
Proportional Hazards Models
Retrospective Studies
Treatment Outcome
Hepatocellular carcinoma
Liver resection
Liver transplantation
Meta-analysis
Statins
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
21 Jan 2022
21 Jan 2022
Historique:
received:
29
09
2021
accepted:
05
01
2022
entrez:
22
1
2022
pubmed:
23
1
2022
medline:
3
3
2022
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is the sixth most common form of cancer worldwide. Although surgical treatments have an acceptable cure rate, tumor recurrence is still a challenging issue. In this meta-analysis, we investigated whether statins prevent HCC recurrence following liver surgery. PubMed, Web of Science, EMBASE and Cochrane Central were searched. The Outcome of interest was the HCC recurrence after hepatic surgery. Pooled estimates were represented as hazard ratios (HRs) and odds ratios (ORs) using a random-effects model. Summary effect measures are presented together with their corresponding 95% confidence intervals (CI). The certainty of evidence was evaluated using the Grades of Research, Assessment, Development and Evaluation (GRADE) approach. The literature search retrieved 1362 studies excluding duplicates. Nine retrospective studies including 44,219 patients (2243 in the statin group and 41,976 in the non-statin group) were included in the qualitative analysis. Patients who received statins had a lower rate of recurrence after liver surgery (HR: 0.53; 95% CI: 0.44-0.63; p < 0.001). Moreover, Statins decreased the recurrence 1 year after surgery (OR: 0.27; 95% CI: 0.16-0.47; P < 0.001), 3 years after surgery (OR: 0.22; 95% CI: 0.15-0.33; P < 0.001), and 5 years after surgery (OR: 0.28; 95% CI: 0.19-0.42; P < 0.001). The certainty of evidence for the outcomes was moderate. Statins increase the disease-free survival of patients with HCC after liver surgery. These drugs seem to have chemoprevention effects that decrease the probability of HCC recurrence after liver transplantation or liver resection.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatocellular carcinoma (HCC) is the sixth most common form of cancer worldwide. Although surgical treatments have an acceptable cure rate, tumor recurrence is still a challenging issue. In this meta-analysis, we investigated whether statins prevent HCC recurrence following liver surgery.
METHODS
METHODS
PubMed, Web of Science, EMBASE and Cochrane Central were searched. The Outcome of interest was the HCC recurrence after hepatic surgery. Pooled estimates were represented as hazard ratios (HRs) and odds ratios (ORs) using a random-effects model. Summary effect measures are presented together with their corresponding 95% confidence intervals (CI). The certainty of evidence was evaluated using the Grades of Research, Assessment, Development and Evaluation (GRADE) approach.
RESULTS
RESULTS
The literature search retrieved 1362 studies excluding duplicates. Nine retrospective studies including 44,219 patients (2243 in the statin group and 41,976 in the non-statin group) were included in the qualitative analysis. Patients who received statins had a lower rate of recurrence after liver surgery (HR: 0.53; 95% CI: 0.44-0.63; p < 0.001). Moreover, Statins decreased the recurrence 1 year after surgery (OR: 0.27; 95% CI: 0.16-0.47; P < 0.001), 3 years after surgery (OR: 0.22; 95% CI: 0.15-0.33; P < 0.001), and 5 years after surgery (OR: 0.28; 95% CI: 0.19-0.42; P < 0.001). The certainty of evidence for the outcomes was moderate.
CONCLUSION
CONCLUSIONS
Statins increase the disease-free survival of patients with HCC after liver surgery. These drugs seem to have chemoprevention effects that decrease the probability of HCC recurrence after liver transplantation or liver resection.
Identifiants
pubmed: 35062904
doi: 10.1186/s12885-022-09192-1
pii: 10.1186/s12885-022-09192-1
pmc: PMC8781082
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
91Informations de copyright
© 2022. The Author(s).
Références
J Palliat Care. 2015;31(3):172-6
pubmed: 26514023
Ann Surg Oncol. 2016 Dec;23(Suppl 5):874-883
pubmed: 27541812
J Clin Oncol. 2013 Apr 20;31(12):1514-21
pubmed: 23509319
Int J Biol Markers. 2018 Nov;33(4):423-431
pubmed: 29874983
Pharmacoepidemiol Drug Saf. 2014 Oct;23(10):1101-6
pubmed: 25074765
Medicine (Baltimore). 2015 Oct;94(42):e1801
pubmed: 26496314
Curr Pharm Des. 2006;12(36):4771-83
pubmed: 17168777
Breast Cancer (Dove Med Press). 2017 Dec 01;9:559-565
pubmed: 29238220
Ann Surg. 2002 Mar;235(3):373-82
pubmed: 11882759
Hepatobiliary Surg Nutr. 2016 Dec;5(6):503-505
pubmed: 28124008
Medicine (Baltimore). 2018 Aug;97(34):e11950
pubmed: 30142817
Dig Dis Sci. 2008 Nov;53(11):2989-94
pubmed: 18363104
Ultraschall Med. 2013 Jun;34(3):280-7
pubmed: 23616066
Nat Rev Cancer. 2016 Nov;16(11):718-731
pubmed: 27562463
Hepatology. 2014 Feb;59(2):724-6
pubmed: 23839991
Acta Cardiol Sin. 2016 Nov;32(6):631-639
pubmed: 27899849
JAMA. 2017 Jan 24;317(4):388-406
pubmed: 28118455
Liver Int. 2017 Aug;37(8):1157-1166
pubmed: 28061016
Surgery. 2018 Feb;163(2):264-269
pubmed: 29167018
BMC Cancer. 2021 Jan 15;21(1):70
pubmed: 33446127
Biosci Trends. 2017 Nov 20;11(5):574-580
pubmed: 29081488
Int J Mol Sci. 2013 Jan 08;14(1):1105-18
pubmed: 23299437
J Hepatol. 2006 Jan;44(1):158-66
pubmed: 16290309
Sci Rep. 2019 Feb 6;9(1):1467
pubmed: 30728421
Gastroenterol Hepatol (N Y). 2019 Apr;15(4):190-193
pubmed: 31435196
Sci Rep. 2021 Feb 8;11(1):3279
pubmed: 33558606
Medicine (Baltimore). 2016 Sep;95(36):e4639
pubmed: 27603355
Nat Rev Cancer. 2005 Dec;5(12):930-42
pubmed: 16341084
Langenbecks Arch Surg. 2021 Sep;406(6):1723-1731
pubmed: 34129108
J Clin Gastroenterol. 2021 Feb 17;:
pubmed: 33606428
Gastroenterology. 2012 May;142(6):1264-1273.e1
pubmed: 22537432
JAMA. 2012 Nov 14;308(18):1906-14
pubmed: 23162861
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Transplant Proc. 2010 Nov;42(9):3823-7
pubmed: 21094864
Ann Surg. 2015 Mar;261(3):521-6
pubmed: 24950265
Expert Rev Gastroenterol Hepatol. 2013 Aug;7(6):493-5
pubmed: 23984995
N Engl J Med. 2012 Nov 8;367(19):1792-802
pubmed: 23134381
Sci Rep. 2020 Jun 1;10(1):8847
pubmed: 32483357
Curr Cancer Drug Targets. 2005 Dec;5(8):579-94
pubmed: 16375664
Trends Immunol. 2007 Feb;28(2):88-98
pubmed: 17197237
Clin Gastroenterol Hepatol. 2019 Sep;17(10):2117-2125.e3
pubmed: 30625400
J Hepatol. 2018 Mar;68(3):476-484
pubmed: 29107150
J Hepatol. 2012 Feb;56(2):412-8
pubmed: 21756858
Am J Gastroenterol. 2011 May;106(5):894-8
pubmed: 21157439
Gastroenterology. 2019 May;156(6):1693-1706.e12
pubmed: 30660733
Br J Clin Pharmacol. 2001 Aug;52(2):213-5
pubmed: 11488782
Liver Cancer. 2016 Oct;5(4):245-256
pubmed: 27781197
HPB (Oxford). 2005;7(1):42-9
pubmed: 18333160
World J Gastroenterol. 2016 Jul 21;22(27):6201-13
pubmed: 27468210
J Hepatol. 2018 Mar;68(3):526-549
pubmed: 28989095
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Formos Med Assoc. 2020 Jan;119(1 Pt 2):218-229
pubmed: 31104872
J Gastroenterol Hepatol. 2009 Mar;24(3):346-53
pubmed: 19220670
Contemp Oncol (Pozn). 2015;19(3):167-75
pubmed: 26557755
BMJ Open. 2014 Sep 16;4(9):e005399
pubmed: 25227628
Med Oncol. 2016 Nov;33(11):123
pubmed: 27734263
Liver Cancer. 2016 Nov;6(1):44-50
pubmed: 27995087
Ann Surg. 2011 Mar;253(3):453-69
pubmed: 21263310
Updates Surg. 2016 Jun;68(2):191-7
pubmed: 27164985
Liver Int. 2017 Feb;37(2):259-270
pubmed: 27427866
Int J Surg. 2010;8(5):336-41
pubmed: 20171303